Loading…
Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance
The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described. The inhibitors are designed to effectively fill in the hydrophobic pocket in the S1′−S2′ subsites and retain all major hydrogen bonding interactions with the...
Saved in:
Published in: | Journal of medicinal chemistry 2009-12, Vol.52 (23), p.7689-7705 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3 |
---|---|
cites | cdi_FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3 |
container_end_page | 7705 |
container_issue | 23 |
container_start_page | 7689 |
container_title | Journal of medicinal chemistry |
container_volume | 52 |
creator | Ghosh, Arun K Kulkarni, Sarang Anderson, David D Hong, Lin Baldridge, Abigail Wang, Yuan-Fang Chumanevich, Alexander A Kovalevsky, Andrey Y Tojo, Yasushi Amano, Masayuki Koh, Yasuhiro Tang, Jordan Weber, Irene T Mitsuya, Hiroaki |
description | The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described. The inhibitors are designed to effectively fill in the hydrophobic pocket in the S1′−S2′ subsites and retain all major hydrogen bonding interactions with the protein backbone similar to darunavir (1) or inhibitor 2. The ring size, the effect of methyl substitution, and unsaturation within the macrocyclic ring structure were assessed. In general, cyclic inhibitors were significantly more potent than their acyclic homologues, saturated rings were less active than their unsaturated analogues and a preference for 10- and 13-membered macrocylic rings was revealed. The addition of methyl substituents resulted in a reduction of potency. Both inhibitors 14b and 14c exhibited marked enzyme inhibitory and antiviral activity, and they exerted potent activity against multidrug-resistant HIV-1 variants. Protein−ligand X-ray structures of inhibitors 2 and 14c provided critical molecular insights into the ligand-binding site interactions. |
doi_str_mv | 10.1021/jm900695w |
format | article |
fullrecord | <record><control><sourceid>acs_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_1006098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>b225873186</sourcerecordid><originalsourceid>FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3</originalsourceid><addsrcrecordid>eNptkUuOEzEQhi0EYsLAggsgC4kFUhr8Sj-WkBmYSOEhAohdq9pdnTjqtke2e1DfgDXn4TScBEeJZjasqlT6VFX__xPylLNXnAn-ej9UjOXV4uc9MuMLwTJVMnWfzBgTIhO5kGfkUQh7xpjkQj4kZ7wqVF7lckb-XGAwWzunm8nGXerDnH72LqKxf3_9Xpst2Jb-yDxMdBP9qOPocU4Pw7fG9W5rNPT08gb6EaJxlrqOAt2gNxgO_Ud3gz39ANo7PeneaHo1DmDpahhG61rsjDZo9US_Gz-GjB9vQ0C6sjvTmOh8oNHRpRsaiPTCj1v65fBlBKvxMXnQQR_wyamek2_vLr8ur7L1p_er5Zt1BqoQMVO6VFWHqXSiKDhbNEUjZaFEi7lqsBBlyQuJwLkssJHAm06xfCF0qxSHtpXn5PlxrwvR1EGbiHqnnbWoY82T9awqE_TyCCWtIXjs6mtvBvBTIupDTPVtTIl9dmSvx2bA9o485ZKAFycAQnK480muCbecEIKVbMHuONCh3rvR2-TDfw7-A1HcqYo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)</source><creator>Ghosh, Arun K ; Kulkarni, Sarang ; Anderson, David D ; Hong, Lin ; Baldridge, Abigail ; Wang, Yuan-Fang ; Chumanevich, Alexander A ; Kovalevsky, Andrey Y ; Tojo, Yasushi ; Amano, Masayuki ; Koh, Yasuhiro ; Tang, Jordan ; Weber, Irene T ; Mitsuya, Hiroaki</creator><creatorcontrib>Ghosh, Arun K ; Kulkarni, Sarang ; Anderson, David D ; Hong, Lin ; Baldridge, Abigail ; Wang, Yuan-Fang ; Chumanevich, Alexander A ; Kovalevsky, Andrey Y ; Tojo, Yasushi ; Amano, Masayuki ; Koh, Yasuhiro ; Tang, Jordan ; Weber, Irene T ; Mitsuya, Hiroaki ; Argonne National Lab. (ANL), Argonne, IL (United States)</creatorcontrib><description>The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described. The inhibitors are designed to effectively fill in the hydrophobic pocket in the S1′−S2′ subsites and retain all major hydrogen bonding interactions with the protein backbone similar to darunavir (1) or inhibitor 2. The ring size, the effect of methyl substitution, and unsaturation within the macrocyclic ring structure were assessed. In general, cyclic inhibitors were significantly more potent than their acyclic homologues, saturated rings were less active than their unsaturated analogues and a preference for 10- and 13-membered macrocylic rings was revealed. The addition of methyl substituents resulted in a reduction of potency. Both inhibitors 14b and 14c exhibited marked enzyme inhibitory and antiviral activity, and they exerted potent activity against multidrug-resistant HIV-1 variants. Protein−ligand X-ray structures of inhibitors 2 and 14c provided critical molecular insights into the ligand-binding site interactions.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm900695w</identifier><identifier>PMID: 19746963</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Columbus, OH: American Chemical Society</publisher><subject>08 HYDROGEN ; AIDS VIRUS ; Anti-HIV Agents - chemical synthesis ; Anti-HIV Agents - chemistry ; Anti-HIV Agents - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; BONDING ; Cell Line ; Crystallography, X-Ray ; DESIGN ; Drug Design ; Drug Resistance, Viral - drug effects ; ENZYMES ; EVALUATION ; HIV Protease - chemistry ; HIV Protease - genetics ; HIV Protease - metabolism ; HIV Protease Inhibitors - chemical synthesis ; HIV Protease Inhibitors - chemistry ; HIV Protease Inhibitors - pharmacology ; HIV-1 - drug effects ; HIV-1 - enzymology ; HIV-1 - genetics ; Humans ; HYDROGEN ; Ligands ; Macrocyclic Compounds - chemical synthesis ; Macrocyclic Compounds - chemistry ; Macrocyclic Compounds - pharmacology ; Medical sciences ; Models, Molecular ; Molecular Conformation ; Mutation ; Pharmacology. Drug treatments ; PROTEINS ; SYNTHESIS</subject><ispartof>Journal of medicinal chemistry, 2009-12, Vol.52 (23), p.7689-7705</ispartof><rights>Copyright © 2009 American Chemical Society</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3</citedby><cites>FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22208050$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19746963$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/1006098$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghosh, Arun K</creatorcontrib><creatorcontrib>Kulkarni, Sarang</creatorcontrib><creatorcontrib>Anderson, David D</creatorcontrib><creatorcontrib>Hong, Lin</creatorcontrib><creatorcontrib>Baldridge, Abigail</creatorcontrib><creatorcontrib>Wang, Yuan-Fang</creatorcontrib><creatorcontrib>Chumanevich, Alexander A</creatorcontrib><creatorcontrib>Kovalevsky, Andrey Y</creatorcontrib><creatorcontrib>Tojo, Yasushi</creatorcontrib><creatorcontrib>Amano, Masayuki</creatorcontrib><creatorcontrib>Koh, Yasuhiro</creatorcontrib><creatorcontrib>Tang, Jordan</creatorcontrib><creatorcontrib>Weber, Irene T</creatorcontrib><creatorcontrib>Mitsuya, Hiroaki</creatorcontrib><creatorcontrib>Argonne National Lab. (ANL), Argonne, IL (United States)</creatorcontrib><title>Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described. The inhibitors are designed to effectively fill in the hydrophobic pocket in the S1′−S2′ subsites and retain all major hydrogen bonding interactions with the protein backbone similar to darunavir (1) or inhibitor 2. The ring size, the effect of methyl substitution, and unsaturation within the macrocyclic ring structure were assessed. In general, cyclic inhibitors were significantly more potent than their acyclic homologues, saturated rings were less active than their unsaturated analogues and a preference for 10- and 13-membered macrocylic rings was revealed. The addition of methyl substituents resulted in a reduction of potency. Both inhibitors 14b and 14c exhibited marked enzyme inhibitory and antiviral activity, and they exerted potent activity against multidrug-resistant HIV-1 variants. Protein−ligand X-ray structures of inhibitors 2 and 14c provided critical molecular insights into the ligand-binding site interactions.</description><subject>08 HYDROGEN</subject><subject>AIDS VIRUS</subject><subject>Anti-HIV Agents - chemical synthesis</subject><subject>Anti-HIV Agents - chemistry</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>BONDING</subject><subject>Cell Line</subject><subject>Crystallography, X-Ray</subject><subject>DESIGN</subject><subject>Drug Design</subject><subject>Drug Resistance, Viral - drug effects</subject><subject>ENZYMES</subject><subject>EVALUATION</subject><subject>HIV Protease - chemistry</subject><subject>HIV Protease - genetics</subject><subject>HIV Protease - metabolism</subject><subject>HIV Protease Inhibitors - chemical synthesis</subject><subject>HIV Protease Inhibitors - chemistry</subject><subject>HIV Protease Inhibitors - pharmacology</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - enzymology</subject><subject>HIV-1 - genetics</subject><subject>Humans</subject><subject>HYDROGEN</subject><subject>Ligands</subject><subject>Macrocyclic Compounds - chemical synthesis</subject><subject>Macrocyclic Compounds - chemistry</subject><subject>Macrocyclic Compounds - pharmacology</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Molecular Conformation</subject><subject>Mutation</subject><subject>Pharmacology. Drug treatments</subject><subject>PROTEINS</subject><subject>SYNTHESIS</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNptkUuOEzEQhi0EYsLAggsgC4kFUhr8Sj-WkBmYSOEhAohdq9pdnTjqtke2e1DfgDXn4TScBEeJZjasqlT6VFX__xPylLNXnAn-ej9UjOXV4uc9MuMLwTJVMnWfzBgTIhO5kGfkUQh7xpjkQj4kZ7wqVF7lckb-XGAwWzunm8nGXerDnH72LqKxf3_9Xpst2Jb-yDxMdBP9qOPocU4Pw7fG9W5rNPT08gb6EaJxlrqOAt2gNxgO_Ud3gz39ANo7PeneaHo1DmDpahhG61rsjDZo9US_Gz-GjB9vQ0C6sjvTmOh8oNHRpRsaiPTCj1v65fBlBKvxMXnQQR_wyamek2_vLr8ur7L1p_er5Zt1BqoQMVO6VFWHqXSiKDhbNEUjZaFEi7lqsBBlyQuJwLkssJHAm06xfCF0qxSHtpXn5PlxrwvR1EGbiHqnnbWoY82T9awqE_TyCCWtIXjs6mtvBvBTIupDTPVtTIl9dmSvx2bA9o485ZKAFycAQnK480muCbecEIKVbMHuONCh3rvR2-TDfw7-A1HcqYo</recordid><startdate>20091210</startdate><enddate>20091210</enddate><creator>Ghosh, Arun K</creator><creator>Kulkarni, Sarang</creator><creator>Anderson, David D</creator><creator>Hong, Lin</creator><creator>Baldridge, Abigail</creator><creator>Wang, Yuan-Fang</creator><creator>Chumanevich, Alexander A</creator><creator>Kovalevsky, Andrey Y</creator><creator>Tojo, Yasushi</creator><creator>Amano, Masayuki</creator><creator>Koh, Yasuhiro</creator><creator>Tang, Jordan</creator><creator>Weber, Irene T</creator><creator>Mitsuya, Hiroaki</creator><general>American Chemical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>OTOTI</scope></search><sort><creationdate>20091210</creationdate><title>Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance</title><author>Ghosh, Arun K ; Kulkarni, Sarang ; Anderson, David D ; Hong, Lin ; Baldridge, Abigail ; Wang, Yuan-Fang ; Chumanevich, Alexander A ; Kovalevsky, Andrey Y ; Tojo, Yasushi ; Amano, Masayuki ; Koh, Yasuhiro ; Tang, Jordan ; Weber, Irene T ; Mitsuya, Hiroaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>08 HYDROGEN</topic><topic>AIDS VIRUS</topic><topic>Anti-HIV Agents - chemical synthesis</topic><topic>Anti-HIV Agents - chemistry</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>BONDING</topic><topic>Cell Line</topic><topic>Crystallography, X-Ray</topic><topic>DESIGN</topic><topic>Drug Design</topic><topic>Drug Resistance, Viral - drug effects</topic><topic>ENZYMES</topic><topic>EVALUATION</topic><topic>HIV Protease - chemistry</topic><topic>HIV Protease - genetics</topic><topic>HIV Protease - metabolism</topic><topic>HIV Protease Inhibitors - chemical synthesis</topic><topic>HIV Protease Inhibitors - chemistry</topic><topic>HIV Protease Inhibitors - pharmacology</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - enzymology</topic><topic>HIV-1 - genetics</topic><topic>Humans</topic><topic>HYDROGEN</topic><topic>Ligands</topic><topic>Macrocyclic Compounds - chemical synthesis</topic><topic>Macrocyclic Compounds - chemistry</topic><topic>Macrocyclic Compounds - pharmacology</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Molecular Conformation</topic><topic>Mutation</topic><topic>Pharmacology. Drug treatments</topic><topic>PROTEINS</topic><topic>SYNTHESIS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghosh, Arun K</creatorcontrib><creatorcontrib>Kulkarni, Sarang</creatorcontrib><creatorcontrib>Anderson, David D</creatorcontrib><creatorcontrib>Hong, Lin</creatorcontrib><creatorcontrib>Baldridge, Abigail</creatorcontrib><creatorcontrib>Wang, Yuan-Fang</creatorcontrib><creatorcontrib>Chumanevich, Alexander A</creatorcontrib><creatorcontrib>Kovalevsky, Andrey Y</creatorcontrib><creatorcontrib>Tojo, Yasushi</creatorcontrib><creatorcontrib>Amano, Masayuki</creatorcontrib><creatorcontrib>Koh, Yasuhiro</creatorcontrib><creatorcontrib>Tang, Jordan</creatorcontrib><creatorcontrib>Weber, Irene T</creatorcontrib><creatorcontrib>Mitsuya, Hiroaki</creatorcontrib><creatorcontrib>Argonne National Lab. (ANL), Argonne, IL (United States)</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>OSTI.GOV</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghosh, Arun K</au><au>Kulkarni, Sarang</au><au>Anderson, David D</au><au>Hong, Lin</au><au>Baldridge, Abigail</au><au>Wang, Yuan-Fang</au><au>Chumanevich, Alexander A</au><au>Kovalevsky, Andrey Y</au><au>Tojo, Yasushi</au><au>Amano, Masayuki</au><au>Koh, Yasuhiro</au><au>Tang, Jordan</au><au>Weber, Irene T</au><au>Mitsuya, Hiroaki</au><aucorp>Argonne National Lab. (ANL), Argonne, IL (United States)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2009-12-10</date><risdate>2009</risdate><volume>52</volume><issue>23</issue><spage>7689</spage><epage>7705</epage><pages>7689-7705</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described. The inhibitors are designed to effectively fill in the hydrophobic pocket in the S1′−S2′ subsites and retain all major hydrogen bonding interactions with the protein backbone similar to darunavir (1) or inhibitor 2. The ring size, the effect of methyl substitution, and unsaturation within the macrocyclic ring structure were assessed. In general, cyclic inhibitors were significantly more potent than their acyclic homologues, saturated rings were less active than their unsaturated analogues and a preference for 10- and 13-membered macrocylic rings was revealed. The addition of methyl substituents resulted in a reduction of potency. Both inhibitors 14b and 14c exhibited marked enzyme inhibitory and antiviral activity, and they exerted potent activity against multidrug-resistant HIV-1 variants. Protein−ligand X-ray structures of inhibitors 2 and 14c provided critical molecular insights into the ligand-binding site interactions.</abstract><cop>Columbus, OH</cop><pub>American Chemical Society</pub><pmid>19746963</pmid><doi>10.1021/jm900695w</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 2009-12, Vol.52 (23), p.7689-7705 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_osti_scitechconnect_1006098 |
source | American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list) |
subjects | 08 HYDROGEN AIDS VIRUS Anti-HIV Agents - chemical synthesis Anti-HIV Agents - chemistry Anti-HIV Agents - pharmacology Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences BONDING Cell Line Crystallography, X-Ray DESIGN Drug Design Drug Resistance, Viral - drug effects ENZYMES EVALUATION HIV Protease - chemistry HIV Protease - genetics HIV Protease - metabolism HIV Protease Inhibitors - chemical synthesis HIV Protease Inhibitors - chemistry HIV Protease Inhibitors - pharmacology HIV-1 - drug effects HIV-1 - enzymology HIV-1 - genetics Humans HYDROGEN Ligands Macrocyclic Compounds - chemical synthesis Macrocyclic Compounds - chemistry Macrocyclic Compounds - pharmacology Medical sciences Models, Molecular Molecular Conformation Mutation Pharmacology. Drug treatments PROTEINS SYNTHESIS |
title | Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A41%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20Synthesis,%20Protein%E2%88%92Ligand%20X-ray%20Structure,%20and%20Biological%20Evaluation%20of%20a%20Series%20of%20Novel%20Macrocyclic%20Human%20Immunodeficiency%20Virus-1%20Protease%20Inhibitors%20to%20Combat%20Drug%20Resistance&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Ghosh,%20Arun%20K&rft.aucorp=Argonne%20National%20Lab.%20(ANL),%20Argonne,%20IL%20(United%20States)&rft.date=2009-12-10&rft.volume=52&rft.issue=23&rft.spage=7689&rft.epage=7705&rft.pages=7689-7705&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm900695w&rft_dat=%3Cacs_osti_%3Eb225873186%3C/acs_osti_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19746963&rfr_iscdi=true |